Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NY-ESO-1 Peptide vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| NY-ESO-1 Peptide vaccine plus Toripalimab-tpzi | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NY-ESO-1 Peptide vaccine | BIOLOGICAL | 300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks. |
| Toripalimab-tpzi | DRUG | 240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine |
Inclusion Criteria: 1. Be able and willing to provide written and signed informed consent prior to performing any protocol-related procedures, including screening evaluations. 2. Women, 18 years or older, with stage III / IV platinum-refractory Ovarian Cancer (OC) (progressed on a platinum containi...
NY-ESO-1 Peptide vaccine is being studied for use in ovarian cancer, specifically in patients with Stage IV ovarian cancer. The investigational therapy is part of a combination strategy being evaluated in a Phase 2 clinical trial to prevent resistance to anti-PD-1 therapy in metastatic ovarian cancer patients.
NY-ESO-1 Peptide vaccine is being developed by Coherus Oncology, Inc., a company traded under the ticker symbol CHRS. The company is conducting a Phase 2 clinical trial of the vaccine in patients with advanced ovarian cancer.
NY-ESO-1 Peptide vaccine is currently in Phase 2 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials for safety and efficacy in ovarian cancer.
NY-ESO-1 Peptide vaccine is being evaluated in a single Phase 2 clinical trial with the identifier NCT05479045. The trial, titled "A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients," is not yet recruiting and plans to enroll 24 female patients in the United States.
NY-ESO-1 Peptide vaccine is designed to target the NY-ESO-1 antigen, a tumor-associated antigen expressed in various cancers. By targeting this antigen, the vaccine aims to stimulate an immune response against cancer cells, potentially helping to prevent resistance to anti-PD-1 therapy in ovarian cancer patients.